Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPIRE-02 empagliflozin extension in refractory diabetes with insulin resistance
jRCT2051190094Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in Insulin Resistance Syndrome Type A (TAIRS), insulin resistance syndrome type B (TBIRS), cardiometabolic risk (CMR) and 2 more, sponsored by Boehringer Ingelheim. Started Mar 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
Insulin Resistance Syndrome Type A (TAIRS)insulin resistance syndrome type B (TBIRS)cardiometabolic risk (CMR)lipoatrophic diabetes (LDM)diabetes mellitus (DM)
Beyond the preview
Go deeper on jRCT2051190094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190094.